Dermago takes over laboratory furniture of Life Science Inkubator GmbH in Bonn to build up their own analytical laboratory
Strausberg, 12 July 2022
The pharmaceutical company DERMAGO GmbH, based in Strausberg, Brandenburg, acquired around 300 m2 of laboratory furniture from Life Science Inkubator GmbH, Bonn, in June 2022. The equipment became available due to the discontinuation of LSI’s incubation activities and is to be reassembled in DERMAGO GmbH’s new laboratory facilities at the Strausberg site. The company expects the construction work to be completed by the 4th quarter of 2022.
With this investment in the Strausberg site, DERMAGO intends to carry out the pharma analytics in-house for its subsidiaries Aresus Pharma, Skin Care Pharma and Degode Pharma in the future and expects significant cost savings as a result. In addition, Dermago will also offer the analytical services to external companies.
The establishment of the infrastructure as well as further product development will be co-financed through the company’s capital round concluded via Companisto in June 2022.
About DERMAGO
DERMAGO GmbH is a service company that has been specializing in the development of unique generic versions and originator preparations of prescription, reimbursable dermatological pharmaceuticals and in independently advancing these through the pharmaceutical approval process. The services of DERMAGO GmbH also include consulting activities, scientific assessments, the preparation of expert reports as well as qualitative and quantitative studies especially for dermatological pharmaceuticals. The development of analytical methods and procedures as well as services for obtaining marketing authorization for pharmaceutical products are also part of the range of the company’s activities.
About LSI Life Science Inkubator
In a trial phase lasting more than 10 years, the Bonn-based Life Science Inkubator GmbH (LSI) built up a unique incubation concept for people interested in founding a company. Innovative projects in the fields of biotechnology, pharmaceuticals and medical technology were evaluated at an early stage and developed together with the project group until they were ready for financing and market launch. After completion of the instrument testing in June 2022, the Life Science Inkubator discontinued its incubation activities. The spin-offs that have emerged from the incubation in recent years will continue to be managed by the incubator’s investment company, LSI Pre-Seed-Fonds GmbH.
Press contact:
DERMAGO GmbH
Kastanienallee 46
15344 Strausberg
Email:info@dermago-group.com
Phone: 03341-589 90 40